Latest News About - Haematology and pathology devices

 
Show/hide duplicate news articles.
Filter by countryfromabout
<<10<12345678910>>>10
 
Show/hide duplicate news articles.
<<10<12345678910>>>10

Tools

Load latest edition

Monday, March 18, 2019

10:38:00 PM CET

Subscribe
RSS | MAP

Language Selection

For any category/filter, users can choose:

  1. the language of the categorized news items (e.g. fr and de to display only those news items in French and German)
  2. the language of the user interface (e.g. it for Italian)

In Top Stories, the user can display the largest clusters of news items for one language only (e.g. en shows all clusters in English)

Country Selection

Users can choose:

  1. country mentioned in the news item (articles about a country)
  2. country in which the news item was published (articles from a country)

Languages Collapse menu...Expand menu...Open help...

Select your languages

ar
az
be
bg
bs
ca
cs
da
de
el
en
eo
es
et
fa
fi
fr
ga
ha
he
hi
hr
hu
hy
id
is
it
ja
ka
km
ko
ku
ky
lb
lo
lt
lv
mk
ml
mn
ms
mt
nl
no
pap
pl
ps
pt
ro
ru
rw
se
si
sk
sl
sq
sr
sv
sw
ta
th
tr
uk
ur
vi
zh
all
Show additional languagesHide additional languages

Interface:

Quotes... Extracted quotes

Riccardo Masetti spiega: “La diffusione di batteri resistenti agli antibiotici è un problema di portata globale che si rivela particolarmente rilevante nei pazienti ematologici, i quali sono infatti costretti a sottoporsi a frequenti profilassi e trattamenti antimicrobici” External link

insalutenews Monday, March 18, 2019 4:53:00 PM CET

Riccardo Masetti continua: “L’esposizione prolungata all’ambiente ospedaliero – (\*) – può favorire l’accumulo di geni con caratteristiche di antibiotico-resistenza nel patrimonio genetico dei batteri che costituiscono il microbiota intestinale. Questa temporanea colonizzazione, soprattutto in pazienti con difese immunitarie già ridotte, può contribuire all’instaurarsi di infezioni e di conseguenza all’aumento del tasso di mortalità a seguito di un’operazione di trapianto” External link

insalutenews Monday, March 18, 2019 4:53:00 PM CET

Riccardo Masetti aggiunge: “Il ventaglio di resistenze presenti nel post-trapianto – (\*) – ha mostrato caratteristiche diverse in ogni paziente. Per questo possiamo immaginare che in futuro sarà possibile proporre terapie e profilassi antibiotiche adeguate per ogni singolo paziente a partire dallo screening delle resistenze presenti all’interno del microbiota intestinale” External link

insalutenews Monday, March 18, 2019 4:53:00 PM CET

Riccardo Masetti spiega: “La diffusione di batteri resistenti agli antibiotici è un problema di portata globale che si rivela particolarmente rilevante nei pazienti ematologici, i quali sono infatti costretti a sottoporsi a frequenti profilassi e trattamenti antimicrobici” External link

lescienze Monday, March 18, 2019 2:50:00 PM CET

Riccardo Masetti aggiunge: "Il ventaglio di resistenze presenti nel post-trapianto - (\*) - ha mostrato caratteristiche diverse in ogni paziente. Per questo possiamo immaginare che in futuro sarà possibile proporre terapie e profilassi antibiotiche adeguate per ogni singolo paziente a partire dallo screening delle resistenze presenti all’interno del microbiota intestinale" External link

lescienze Monday, March 18, 2019 2:50:00 PM CET

Robert Farra said: "We are delighted that Peter has joined the CeQur board," External link

prnewswire Monday, March 18, 2019 2:07:00 PM CET

Joseph Biden said: “I was stunned when my son for a year was battling stage 4 glioblastoma,” “I couldn’t get his records. I’m the vice president of the United States of America. … It was an absolute nightmare. It was ridiculous, absolutely ridiculous, that we’re in that circumstance” External link

kaiserhealthnews Monday, March 18, 2019 9:50:00 AM CET

Glen Tullman said: “It was a big distraction. That was an unintended consequence of that,” “All the companies were saying, This is a one-time opportunity to expand our share, focus everything there, and then we’ll go back and fix it” External link

kaiserhealthnews Monday, March 18, 2019 9:50:00 AM CET

John Halamka said: “Every single idea was well-meaning and potentially of societal benefit, but the combined burden of all of them hitting clinicians simultaneously made office practice basically impossible,” External link

kaiserhealthnews Monday, March 18, 2019 9:50:00 AM CET

John Henry asked: “You’re sitting in front of a patient, and there are so many things you have to do, and you only have so much time to do it in — seven to 11 minutes, probably — so when do you really listen?” External link

kaiserhealthnews Monday, March 18, 2019 9:50:00 AM CET

Robert Ward said: “The need for advances in the treatment of bloodstream infections have, until now, gone largely unmet. However, ExThera’s technology has repeatedly shown promise in preclinical studies and clinical testing as a safe and effective option,” External link

4-traders Monday, March 18, 2019 8:38:00 AM CET

Andrew M Weiss commented: "ReCor is encouraged by the SOLO 6 month outcome data as it is the first randomized, blinded, sham-controlled evidence of the effectiveness of the Paradise renal denervation system in combination with added anti-hypertensive medication. These data demonstrate the 6 month durability of the blood pressure lowering effect of the Paradise renal denervation system, either alone or in combination with medications," "We are also excited that we have begun to randomize subjects in our RADIANCE-II pivotal study, which we plan to complete in 2020. The combination of our independent, blinded and sham-controlled RADIANCE-HTN SOLO and TRIO studies, the REQUIRE study being run in Japan and Korea, and our pivotal RADIANCE-II study will provide safety and efficacy outcomes on more than 600 patients, covering a broad range of patients with hypertension. If successful, we hope that, in the future, these studies may support an important new treatment option for millions of hypertensive patients worldwide" External link

finanzen-ch Sunday, March 17, 2019 3:37:00 PM CET

Massimo Scaccabarozzi continua: «Mi auguro che tutto questo possa continuare – (\*) - con un’attenta gestione del finanziamento del Ssn e un occhio di riguardo alla ricerca, che porterà innovazioni mai viste prima» External link

ilSole24ore Friday, March 8, 2019 7:09:00 PM CET

Jeffrey Miller explicó: «La presentación de la solicitud de aprobación del cambio parcial del Ensayo de mutación LeukoStrat CDx FLT3 y la continuación de la asociación con Daiichi Sankyo representan hitos significativos para nuestra empresa. Seguimos dando la bienvenida a la oportunidad de asociarnos con empresas farmacéuticas mundiales interesadas en desarrollar y comercializar diagnósticos complementarios, ya sea para enfermedades hematológicas o tumores sólidos» External link

efe-agencia Monday, November 19, 2018 2:34:00 PM CET

Most associated names

Daily number of articles in this category

Trend data not available for this selection.